The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Expert Q&A: Dr. Michael Lockshin on APS

Expert Q&A: Dr. Michael Lockshin on APS

November 13, 2015 • By Richard Quinn

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Generic_Practice_Management_500x270As yet, there is insufficient evidence to determine whether the new wave of anticoagulant medications is safe for use in patients with antiphospholipid syndrome (APS), says one expert.

You Might Also Like
  • Potential Biomarker for APS Identified
  • From the Expert: Dr. Michael Weisman Discusses the Challenges of Enthesitis
  • APS: What Rheumatologists Should Know about Hughes Syndrome
Also By This Author
  • Telemedicine: One Rheumatologist’s Experience

According to Michael Lockshin, MD, director of the Barbara Volcker Center for Women and Rheumatic Disease at the Hospital for Special Surgery in New York, although alternatives to warfarin have attracted attention, there is lack of an evidence base to support their use in patients with APS.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We’ve seen a tendency for people to start using these new drugs, possibly because they’re more convenient than the older ways of anticoagulating. But in this moment, if anything, the signals are that they do not work in antiphospholipid [syndrome], but we’re waiting for formal studies,” Dr. Lockshin says in a question and answer interview with The Rheumatologist.

Lockshin_125x150

Dr. Michael Lockshin

Question: Do you want rheumatologists to keep APS in mind?
Answer: Yes. Unequivocally. An issue with [APS] is that, in places in which there is not a recognized expertise, usually the hematologists will take over the care, because it is basically a clotting problem. … So when I talk about the use of the newer anticoagulants, the recommendations have come, mostly, from a hematologist who thinks, “Oh, I can use this for atrial fibrillation, so why can’t I use it in this disease?” They never ask: “Is it the same disease as the other clotting diseases that I’m dealing with?”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Q: How do you combat that approach?
A: Information. Making this [disease] as widely known as possible. Things that we routinely see, that are errors, are casually discontinuing anticoagulation for purposes of doing a test, for instance, a cardiac cath or doing a minor surgery. … You can’t causally discontinue anticoagulation in these patients, even though you can in someone with one of the other types of clotting disorders. So the biggest error I see—and I get this again in referral practice—is someone [assuming], “Oh, it’s like other clotting disorders, so the rules that apply to those other clotting disorders also apply to [APS].” And they don’t. The [APS] patients are much more dangerous to handle.

Q: In terms of that danger, what do you recommend to somebody who is not used to dealing with APS? What is the best practice to move forward?
A: Talk to someone who’s got a lot of experience with the disease. I get telephone calls and emails at least every week from somewhere—pretty much anywhere in the world—asking, “How do I handle such a thing?” I think all of my colleagues are used to getting those. It’s not hard to get information. If you don’t know the disease well, there are a lot of people who are willing to help.

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: anticoagulant, Antiphospholipid Syndrome, APS, Interviewing, MD, Michael Lockshin

You Might Also Like:
  • Potential Biomarker for APS Identified
  • From the Expert: Dr. Michael Weisman Discusses the Challenges of Enthesitis
  • APS: What Rheumatologists Should Know about Hughes Syndrome
  • New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.